These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

143 related items for PubMed ID: 39004952

  • 1. Enzyme replacement therapy for hypophosphatasia-The current paradigm.
    Schindeler A, Ludwig K, Munns CF.
    Clin Endocrinol (Oxf); 2024 Dec; 101(6):593-601. PubMed ID: 39004952
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Hypophosphatasia: From Diagnosis to Treatment.
    Simon S, Resch H, Klaushofer K, Roschger P, Zwerina J, Kocijan R.
    Curr Rheumatol Rep; 2018 Sep 10; 20(11):69. PubMed ID: 30203264
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Asfotase alfa: enzyme replacement for the treatment of bone disease in hypophosphatasia.
    Hofmann C, Seefried L, Jakob F.
    Drugs Today (Barc); 2016 May 10; 52(5):271-85. PubMed ID: 27376160
    [Abstract] [Full Text] [Related]

  • 7. Asfotase Alfa in Perinatal/Infantile-Onset and Juvenile-Onset Hypophosphatasia: A Guide to Its Use in the USA.
    Scott LJ.
    BioDrugs; 2016 Feb 10; 30(1):41-8. PubMed ID: 26832358
    [Abstract] [Full Text] [Related]

  • 8. Profile of asfotase alfa in the treatment of hypophosphatasia: design, development, and place in therapy.
    Bowden SA, Foster BL.
    Drug Des Devel Ther; 2018 Feb 10; 12():3147-3161. PubMed ID: 30288020
    [Abstract] [Full Text] [Related]

  • 9. Efficacy and safety of asfotase alfa in patients with hypophosphatasia: A systematic review.
    Shirinezhad A, Esmaeili S, Azarboo A, Tavakoli Y, Hoveidaei AH, Zareshahi N, Ghaseminejad-Raeini A.
    Bone; 2024 Nov 10; 188():117219. PubMed ID: 39089608
    [Abstract] [Full Text] [Related]

  • 10. Effect of Asfotase Alfa on Muscle Weakness in a Japanese Adult Patient of Hypophosphatasia with Low ALP Levels.
    Koyama H, Yasuda S, Kakoi S, Ohata Y, Shimizu Y, Hasegawa C, Hayakawa A, Akiyama T, Yagi T, Aotani D, Imaeda K, Ozono K, Kataoka H, Tanaka T.
    Intern Med; 2020 Mar 15; 59(6):811-815. PubMed ID: 31787692
    [Abstract] [Full Text] [Related]

  • 11. Asfotase Alfa Treatment Improves Survival for Perinatal and Infantile Hypophosphatasia.
    Whyte MP, Rockman-Greenberg C, Ozono K, Riese R, Moseley S, Melian A, Thompson DD, Bishop N, Hofmann C.
    J Clin Endocrinol Metab; 2016 Jan 15; 101(1):334-42. PubMed ID: 26529632
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Hypophosphatasia: Enzyme Replacement Therapy Brings New Opportunities and New Challenges.
    Whyte MP.
    J Bone Miner Res; 2017 Apr 15; 32(4):667-675. PubMed ID: 28084648
    [Abstract] [Full Text] [Related]

  • 14. Asfotase alfa treatment for 1 year in a 16 year-old male with severe childhood hypophosphatasia.
    Bowden SA, Adler BH.
    Osteoporos Int; 2018 Feb 15; 29(2):511-515. PubMed ID: 29046930
    [Abstract] [Full Text] [Related]

  • 15. Lethal hypophosphatasia successfully treated with enzyme replacement from day 1 after birth.
    Okazaki Y, Kitajima H, Mochizuki N, Kitaoka T, Michigami T, Ozono K.
    Eur J Pediatr; 2016 Mar 15; 175(3):433-7. PubMed ID: 26459154
    [Abstract] [Full Text] [Related]

  • 16. Hypophosphatasia: Canadian update on diagnosis and management.
    Khan AA, Josse R, Kannu P, Villeneuve J, Paul T, Van Uum S, Greenberg CR.
    Osteoporos Int; 2019 Sep 15; 30(9):1713-1722. PubMed ID: 30915507
    [Abstract] [Full Text] [Related]

  • 17. Enzyme replacement for craniofacial skeletal defects and craniosynostosis in murine hypophosphatasia.
    Liu J, Campbell C, Nam HK, Caron A, Yadav MC, Millán JL, Hatch NE.
    Bone; 2015 Sep 15; 78():203-11. PubMed ID: 25959417
    [Abstract] [Full Text] [Related]

  • 18. Five-year efficacy and safety of asfotase alfa therapy for adults and adolescents with hypophosphatasia.
    Kishnani PS, Rockman-Greenberg C, Rauch F, Bhatti MT, Moseley S, Denker AE, Watsky E, Whyte MP.
    Bone; 2019 Apr 15; 121():149-162. PubMed ID: 30576866
    [Abstract] [Full Text] [Related]

  • 19. Status Epilepticus due to Asfotase Alfa Interruption in Perinatal Severe Hypophosphatasia.
    Ogawa E, Shimura K, Yoshihashi H, Miyama S.
    Pediatr Neurol; 2022 May 15; 130():4-6. PubMed ID: 35303588
    [Abstract] [Full Text] [Related]

  • 20. Investigation of ALPL variant states and clinical outcomes: An analysis of adults and adolescents with hypophosphatasia treated with asfotase alfa.
    Kishnani PS, Del Angel G, Zhou S, Rush ET.
    Mol Genet Metab; 2021 May 15; 133(1):113-121. PubMed ID: 33814268
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.